Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Wyoming Healthcare Weekly.
Press releases published on June 25, 2025
Commure Launches Commure Agents – AI Assistants That Fully Automate Physician Workflows
GlobeNewswire
·
June 25, 2025
MOUNTAIN VIEW, Calif., June 25, 2025 (GLOBE NEWSWIRE) -- Commure, a leading healthcare technology company, today announced the commercial launch of Commure Agents, AI-powered colleagues built for healthcare. Commure Agents are intelligent, customizable …
Silo Pharma Enters into Letter of Intent to Form Joint Venture with Hoth Therapeutics to Develop Obesity Treatment Targeting $16 Billion Global Market
GlobeNewswire
·
June 25, 2025
Technology Co-Developed by the U.S. Department of Veterans Affairs and Emory University NEW YORK, June 25, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on novel …
Biodexa Announces Activation of First Clinical Study Site for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)
GlobeNewswire
·
June 25, 2025
June 25, 2025 Biodexa Announces Activation of First Clinical Study Site for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP) Biodexa Pharmaceuticals PLC (“Biodexa” or “the Company”), (Nasdaq: BDRX), a clinical stage biopharmaceutical company …
Adial Pharmaceuticals Secures U.S.-Based Manufacturing Through Agreements with Cambrex and Thermo Fisher Scientific for Drug Substance and Drug Product Supply
GlobeNewswire
·
June 25, 2025
Scope of Agreement with Cambrex to Provide Ondansetron HCL Drug Substance Under FDA Approved Drug Master File Scope Of Agreement With Thermo Fisher to Provide Manufacturing Services Including Demonstration, Clinical, Registration And Validation Batches of …
Hepion Pharmaceuticals Successfully Completes Application to the OTCQB
GlobeNewswire
·
June 25, 2025
MORRISTOWN, N.J., June 25, 2025 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (OTCQB:HEPA), a clinical stage biopharmaceutical company that is developing and commercializing diagnostic tests for celiac disease, respiratory multiplex (Covid/Influenza A/B …
Intelligent Bio Solutions and Spjotgard Drive Rapid Adoption of Fingerprint Drug Testing Across Scandinavia
GlobeNewswire
·
June 25, 2025
NEW YORK, June 25, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, non-invasive drug screening solutions, today announced the success of its ongoing …
Eyenovia Announces Co-Branded Validator with Kinetiq
GlobeNewswire
·
June 25, 2025
LAGUNA HILLS, Calif., June 25, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company”), a pioneer in ophthalmic technologies and the first publicly-listed U.S. company to build a strategic treasury of HYPE, the native token of …
Glucotrack and OneTwo Analytics Present Positive Final Results of First-In-Human Study for Continuous Blood Glucose Monitor at American Diabetes Association’s 85th Scientific Sessions
GlobeNewswire
·
June 25, 2025
RUTHERFORD, N.J. and STOCKHOLM, June 25, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced results …
Ernexa Therapeutics Expands Advisory Board to Form Integrated Scientific and Medical Advisory Board as it Prepares for Clinical Development
GlobeNewswire
·
June 25, 2025
CAMBRIDGE, Mass., June 25, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announced the expansion of its Scientific Advisory Board to a …
Wearable Devices Advances AI Health Monitoring Platform as U.S. HHS Embraces Wearable Tech
GlobeNewswire
·
June 25, 2025
Yokneam Illit, Israel, June 25, 2025 (GLOBE NEWSWIRE) -- Wearable Devices Ltd. (the “Company” or “Wearable Devices”) (Nasdaq: WLDS, WLDSW), a technology growth company specializing in artificial intelligence (“AI”)-powered touchless sensing wearables, …
OneMedNet CEO Aaron Green Issues Letter to Shareholders Highlighting Strategic Progress
GlobeNewswire
·
June 25, 2025
MINNEAPOLIS, June 25, 2025 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (“OneMedNet” or the “Company”), a leader in AI-powered Real-World Data (RWD) announced today that Aaron Green, President and CEO, issued the following letter to …
Mainz Biomed Secures Public Funding to Advance Innovative Pancreatic Cancer Screening Test
GlobeNewswire
·
June 25, 2025
BERKELEY, Calif. and MAINZ, Germany, June 25, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, is pleased to announce that its …
Evaxion expands R&D pipeline with new vaccine program targeting Group A Streptococcus
GlobeNewswire
·
June 25, 2025
Initial computational analysis demonstrated that Evaxion’s AI-Immunology™ platform can identify novel vaccine targets to combat Group A Streptococcus (GAS) New vaccine program is added to Evaxion’s pipeline under the name EVX-B4 Urgent need for preventive …
Arbor Biotechnologies Appoints Mikael Dolsten, M.D., Ph.D., to Board of Directors
GlobeNewswire
·
June 25, 2025
CAMBRIDGE, Mass., June 25, 2025 (GLOBE NEWSWIRE) -- Arbor Biotechnologies™, a biotechnology company discovering and developing the next generation of genetic medicines, today announced the appointment of Mikael Dolsten, M.D., Ph.D., to its Board of …
Assembly Biosciences Reports Positive Topline Results from Phase 1b Clinical Trial of Next-Generation Investigational Capsid Assembly Modulator ABI-4334 in Chronic Hepatitis B
GlobeNewswire
·
June 25, 2025
– Favorable safety and tolerability profile, as well as pharmacokinetics supporting once-daily oral dosing, continued to be observed in final 400 mg cohort – – Mean plasma HBV DNA reductions of 3.2 logs IU/mL over 28 days of treatment for 400 mg cohort …
Corbus Pharmaceuticals Announces First Patient Dosed with its Nectin-4 Targeting ADC CRB-701 in Combination with Pembrolizumab
GlobeNewswire
·
June 25, 2025
Combination cohort initiated following successful review of monotherapy cohort Over 100 participants dosed to-date in monotherapy cohort Priority are Head and Neck Squamous Cell Carcinoma (HNSCC) and cervical cancer Data update on schedule for later this …
Rhythm Pharmaceuticals Announces Three Late-breaking Data Abstracts Accepted for Presentation at ENDO 2025
GlobeNewswire
·
June 25, 2025
BOSTON, June 25, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that three …
ORYZON to Host Virtual KOL Event on July 9, 2025
GlobeNewswire
·
June 25, 2025
MADRID and CAMBRIDGE, Mass., June 25, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and a European leader in epigenetics, announced today that it will host a virtual KOL event on …
Basecamp Research Announces Malawi Biodiscovery Partnership in Series of New Collaborations Across Three Continents at UK Government Nature Action Event
GlobeNewswire
·
June 25, 2025
Partnerships with Malawi, Hungary, and other new partners will rapidly expand BaseData, the largest biological protein database designed specifically for training generative AI foundation models to improve drug discovery and planetary health. …
DIMERx Awarded Up to $15M by NIDA Under NIH HEAL Initiative® to Advance DMX-101 as a Non-Addictive Oral Therapy for Chronic Pain
GlobeNewswire
·
June 25, 2025
SAN FRANCISCO, June 25, 2025 (GLOBE NEWSWIRE) -- DIMERx, Inc., a late-stage biopharmaceutical company entering growth phase, today announced it has been awarded a UG3/UH3 cooperative agreement (UG3DA061645) for up to $15 million from the National Institute …